$SRPT — BUY 📊

$SRPT — BUY 📊 Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and o 🎯 Q2 2026 | Rev $1B | EPS $-3.58 vs $-0.77 🔴 💡 Consensus priced in a moderate miss but not a catastrophic decline. Actual EPS was -3.58 due to non-cash charges or R&D timing, not operational deterioration. The market overreacted, and normalizing these items shows a core business far healthier than the stock implies. 📉 Reward/Risk: 2.3:1 🏢 Business Quality: 6/10 - Strong commercial portfolio and pipeline, but high cash burn and binary clinical risk weigh; revenue growth offsets earnings volatility. 📊 Valuation: fair — P/S appears rich if market cap is $100B, but that figure is inconsistent with the $17.415 price and likely erroneous. 📊 Our read: BUY. Full analysis → https://stockduty.xyz/s/SRPT0623

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and o